Q&A: Pfizer Researcher on the PSTC and Applying Bradford Hill's Principles to Biomarker Development
September 17, 2010
Q&A: Pfizer Researcher on the PSTC and Applying Bradford Hill's Principles to Biomarker Development
ProteoMonitor spoke to Josef Ozer, senior principal scientist at Pfizer, about his work as part of the Predictive Safety Testing Consortium and his recent paper applying Bradford Hill's Principles of Causality Association to biomarker research.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Big Pharma Exploring Targeted MS to Measure Key Transporter Proteins for Drug Development
August 12, 2011 / ProteoMonitor - Correlogic Developing 'Second Generation' OvaCheck; Seeks Ruling on Quest, LabCorp Licenses
July 8, 2011 / ProteoMonitor - Phosphoproteomic Profiling Suggests Src Inhibitors Useful as Kidney Cancer Treatment
June 3, 2011 / ProteoMonitor - Researchers ID Gastric Cancer Biomarker Aimed for Use in DTC Tests in US, China
May 6, 2011 / ProteoMonitor - Bruker Gets Health Canada Approval for IVD MALDI Biotyper, Closes Michrom Acquisition
April 8, 2011 / ProteoMonitor